Atlas Trials

To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors

Clinical trial NCT01922752 · COMPLETED

Trial details

NCT number
NCT01922752
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Solid Tumors
Start date
2013-07-01
Primary completion
2015-09-01
Enrollment
32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.